Abstract
Purpose There remains a need for a standardized dataset for respiratory studies to accelerate data collection, improve research efficiency and aid the sharing, merging and comparison of datasets. This TORPEDO (Towards Optimum Reporting of Pulmonary Effectiveness Databases and Outcomes) project aimed to develop a checklist of optimum and minimum variables for asthma and chronic obstructive pulmonary disease (COPD) research.
Methods A 3-phase modified Delphi survey was conducted: in phase 1, an expert panel generated a list of variables, in phase 2 a Delphi panel selected the minimum variables (>66% agreement) for any design and in phase 3 they were asked to select a minimum set for specific study designs.
Results In phase 1 the expert panel (n=22) proposed 224 variables. In phase 2, voting by 64 participants resulted in consensus (>66% agreement) for 18 variables and partial agreement (50-66%) for 44 variables, following this, 5 technical variables (e.g. date of test) were removed. In phase 3, 34 members of the Delphi panel completed voting; consensus was reached for 13 variables for retrospective asthma studies and 34 for prospective asthma studies. For COPD, there were 16 variables for retrospective studies and 37 for prospective studies. Gender, asthma/COPD exacerbations and patient-reported outcomes were the only variables with 100% agreement for both asthma and COPD studies.
Conclusion The proposed list of minimally required variables will allow the assessment of current data sources for their utility in asthma and COPD studies, facilitate the merging of datasets, aid standardization of data collection and improve research efficiency.
Competing Interest Statement
A. Kaplan is a member of advisory board or speakers bureau for Astra Zeneca, Behring, Boehringer Ingelheim, Covis, GSK, Pfizer, Purdue, Merck Frosst, Novartis, NovoNordisc, Sanofi, Teva, Trudel. J. Kocks reports grants, personal fees and non-financial support from AstraZeneca, grants, personal fees and non-financial support from Boehringer Ingelheim, grants and personal fees from Chiesi Pharmaceuticals, grants, personal fees and non-financial support from GSK, grants and personal fees from Novartis, grants from MundiPharma, grants from TEVA, outside the submitted work; and Janwillem Kocks holds 72.5% of shares in the General Practitioners Research Institute.Dr. Kocks reports grants and non-financial support from AstraZeneca, grants and non-financial support from Boehringer Ingelheim, grants from Chiesi Pharmaceuticals, grants and non-financial support from GSK, grants from Novartis, grants from MundiPharma, grants from TEVA, from null, outside the submitted work; and Janwillem Kocks holds 72.5420:655 of shares in the General Practitioners Research Institute. N. Roche reports grants and personal fees from Boehringer Ingelheim, Novartis, Pfizer and personal fees from Teva, GSK, AstraZeneca, Chiesi, Sanofi, Trudell, Zambon. E. Van Ganse has received consultancy fees from Pelyon Ltd, for unrelated research projects. J. Hurst has received support to attend meeting, and payment for education and advisory work (personally and to his employer, UCL) from pharmaceutical companies that make medicines to treat COPD. M. Roman-Rodriguez reports personal fees and grants from AstraZeneca, Boehringer Ingelheim, GSK, Mundipharma, Novartis, Teva, and Trudell Medical International in the last 3 years. M. Miravitlles has received speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Menarini, Rovi, Bial, Sandoz, Zambon, CSL Behring, Grifols and Novartis, consulting fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Bial, Gebro Pharma, Kamada, CSL Behring, Laboratorios Esteve, Ferrer, Mereo Biopharma, Verona Pharma, TEVA, Spin Therapeutics, pH Pharma, Novartis, Sanofi and Grifols and research grants from GlaxoSmithKline and Grifols. N. Papadopoulos reports personal fees from Novartis, personal fees from Nutricia, personal fees from HAL, personal fees from MENARINI/FAES FARMA, personal fees from SANOFI, personal fees from MYLAN/MEDA, personal fees from BIOMAY, personal fees from AstraZeneca, personal fees from GSK, personal fees from MSD, personal fees from ASIT BIOTECH, personal fees from Boehringer Ingelheim, grants from Gerolymatos International SA, grants from Capricare, outside the submitted work. K. Verhamme works for a research group that received/receives unconditional grants from Yamanouchi, Pfizer/Boehringer Ingelheim, GSK, Novartis none of which are related to the content of this manuscript. All other authors report no other conflicts of interest in relation to this work.
Funding Statement
This study was supported by the Respiratory Effectiveness Group, an international, investigator-led, not-for-profit, real-life respiratory research and advocacy initiative (http://www.regresearchnetwork.org) and the Global Alliance for Chronic Diseases (www.gacd.org).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study involved no patients; participants were all professionals involved in respiratory research who are members of the REG or GACD networks and consented to participate in the Delphi exercise. The study received ethical approval from the Anonymised Data Ethics and Protocol Transparency (ADEPT) Committee (approval number ADEPT0921) (www.regresearchnetwork.org/adept-committee).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: This study was supported by the Respiratory Effectiveness Group, an international, investigator-led, not-for-profit, real-life respiratory research and advocacy initiative (http://www.regresearchnetwork.org) and the Global Alliance for Chronic Diseases (www.gacd.org).
Data Availability
All data produced in the present work are contained in the manuscript
